Bioinformatics.org
[Trainer-Lead Program in Bioinformatics]
Not logged in

Bioinformatics.org
Membership (36910+) Group hosting [?]

Careers
About bioinformatics
Bioinformatics training
Bioinformatics jobs

Research
All information groups
Online databases Online analysis tools Online education tools More tools

Development
All software groups
FTP repository
SVN & CVS repositories [?]
Mailing lists

Forums
News & Commentary
Jobs Forum
(Career Center)

News & Commentary - Message forums

Open Access: Ars Technica: Myriad, fresh off Supreme Court loss, keeps on suing over gene patents
Submitted by J.W. Bizzaro; posted on Saturday, July 13, 2013
Submitter EXCERPT:
But while health advocates expected Myriad's dominance of testing in this area to be over, Myriad and its lawyers see things quite differently. The Supreme Court's allowance of patents on another type of genetic material -- cDNA -- means that Myriad can still stop competitors from offering specific types of tests relating to the genes. It has other, differently worded patents that the competing tests are still infringing, according to Myriad lawyers.

The company is still flush with genetic patents it says remain valid. It originally owned 520 valid patent claims, and the Supreme Court decision merely "reduc[ed] the overall patent estate to 24 patents and 515 patent claims," lawyers wrote in documents filed Tuesday and Wednesday.

SOURCE:
[link]

Expanded view | Monitor forum | Save place

Start a new thread:
You have to be logged in to post a reply.

 

Acknowledgments

We wish to thank the following for their support:

[Scalable Informatics]
[Become a sponsor]
Copyright © 2016 · Scilico, LLC